Its local production ramp-up remains unhurried as demand for boosters reduces
Rising Chinese labour costs, geopolitics, pandemic-stricken uncertainties have forced global players to derisk
Leading contract manufacturing drug firm Akums Drugs & Pharmaceuticals plans to expand its presence globally and enhance product range as it looks to more than double its turnover to Rs 10,000 crore by 2028, as per the company's Joint Managing Director Sandeep Jain. The company, which produces around 12 per cent of all the medicines consumed in the country from its 15 manufacturing facilities, has a topline of about Rs 4,000 crore currently. In an interaction with PTI, Jain said the company would be able to achieve its stated financial targets even if it continues to grow at the same pace it has been doing over the last few years. He noted that the demand for pharmaceutical products is going to stay robust in the domestic market, with some estimates pointing towards the market doubling by 2030. "We expect to touch a turnover of Rs 10,000 crore in the next five years (2028)from the current level of Rs 4,000 crore. Our plan is to keep growing by at least 12-15 (CAGR)," Jain ...
Share of India revenue in home-grown firms' consolidated turnover rising over the years
Govt finalises the draft notification issued in June
Nigeria has reportedly circulated the alert across all professional bodies, health care providers and supply chain associates
The firm already has manufacturing units in four Indian cities, all of which are focused on the export market
Pharma giant Roche believes, its ability to reinvent itself through innovation was behind its success. Business Standard's Sohini Das and Nivedita Mookerji spoke to the members of its founding family
The government had rolled out PLI schemes for 15 key sectors, including technology, textile, automobile, pharmaceutical drugs, speciality steel, electronics, among others
In July, the RBI had unveiled a mechanism to settle international transactions in rupee to promote the growth of global trade, with emphasis on exports from India
Indian Pharmaceutical Alliance ethics committee submits report to NPPA
As part of de-risking their business, they have started reducing the share of ibuprofen in their overall turnover, and add more popular products to the portfolio
The petitioner, while seeking statutory backing to the Uniform Code of Pharmaceutical Marketing Practices (UCPMP), said that corruption in pharma marketing practices is yet unregulated in India
The share of specialty medicines in overall pharmaceutical spending has been consistently increasing over the past decade, from 22 per cent in 2011 to 39 per cent in 2021
Democrats pushed their election-year economic package to Senate passage, a hard-fought compromise less ambitious than Biden's original domestic vision but one that still meets deep-rooted party goals
Bajaj Healthcare said it has received two orders from the central government to produce active pharmaceutical ingredients (API) from poppy capsules and other derivatives on an annual basis
India ranks third worldwide for production in terms of volume and 14th by value, says commerce ministry.
Some of the growth is captured in the price rally, higher valuations
Covid related drugs contributed 40% of the pharma market last year
India's ability to secure not just its own drug supply but that of Africa, the Americas and Europe is at stake